SCHEMBL5175336

SCHEMBL5175336

Cc1ccc(Br)c(S(=O)O)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.35
RAB9A P51151 4/20 0.33
NPC1 O15118 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TRPA1 O75762 1/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
HSP90AA1 P07900 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 4/20 0.32
MAPK1 P28482 2/20 0.32
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
MAPT P10636 3/20 0.32
HPGD P15428 2/20 0.32
PTPN1 P18031 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7653242 0.98 MAOB (0.34) MAOBRAB9ANPC1SMN1; SMN2TRPA1
SCHEMBL7736962 0.80 TRPA1 (0.37) MAOBSMN1; SMN2TRPA1KMT2AMEN1
SCHEMBL8934344 0.78 ALDH1A1 (0.39) NPC1TRPA1KMT2AMEN1L3MBTL1
SCHEMBL5174995 0.78 NMT1 (0.31) MAOBALDH1A1MAPK1CYP1A2CYP2A6
SCHEMBL11343549 0.77 ALDH1A1 (0.38) NPC1TRPA1KMT2AMEN1L3MBTL1
SCHEMBL10826459 0.75 RAB9A (0.40) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL7170552 0.74 TDP1 (0.44) RAB9ANPC1SMN1; SMN2TRPA1KMT2A
SCHEMBL11330503 0.72 TDP1 (0.43) RAB9ANPC1SMN1; SMN2TRPA1KMT2A
SCHEMBL10826657 0.72 ACHE (0.52) SMN1; SMN2KMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL8814202 0.72 HTT (0.41) RAB9AL3MBTL1ALDH1A1MAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1097141-B1 IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT SANOFI AVENTIS DEUTSCHLAND (DE) 2007-05-23 EP disclosed
CN-1231465-C Biphenylsulfonyl cyanamides, method for the production thereof and use thereof as medicaments AVENTIS PHARMACEUTIC DEUTSCHLA (DE) 2005-12-14 CN disclosed
CN-1211370-C Imidazole derivatives with biphenylsulfonyl substituents, process for their preparation and their use as pharmaceuticals or diagnostic agents AVENTIS PHARMA GMBH (DE) 2005-07-20 CN disclosed
CN-1177827-C Biphenylsulfonyl-substd. imidazole derivs., their preparation process, their use as drug or diagnostic agent and drug contg. them ���ĵ�˹ҩ��¹����޹�˾ 2004-12-01 CN disclosed
EP-1097140-B1 BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM AVENTIS PHARMA GMBH (DE) 2004-03-03 EP disclosed
EP-1053224-B1 BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT AVENTIS PHARMA GMBH (DE) 2002-08-21 EP disclosed
US-6372917-B1 INHIBIT CELLULAR SODIUM ION-DEPENDENT CHLORIDE ION/BICARBONATE-EXCHANGE MECHANISM OR SODIUM/BICARBONATE SYMPORTER; TREATMENT OF ALL ACUTE OR CHRONIC DAMAGE CAUSED BY ISCHEMIA OR ILLNESSES INDUCED THEREBY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-16 US disclosed
US-6369236-B1 DRUG FOR MEDICAL DIAGNOSIS ANTIARRHYTHMIC PROPRIETIES AND CONTAIN A CARDIOPROTECTIVE COMPOUND. THEY CAN PREVENTIVELY INHIBIT OR STRONGLY REDUCE PATHOPHYSIOLOGIC PROCESSES UPON OCCURRENCE OF ISCHEMIC INJURIES, ESPECIALLY ISCHEMIC CARDIAC AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-6369069-B1 CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
CN-1309644-A Biphenylsulfonyl-substituted imidazole derivatives, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them AVENTIS PHARMA GMBH (DE) 2001-08-22 CN disclosed
CN-1309645-A Imidazole derivatives with biphenylsulfonyl substituents, process for their preparation and their use as pharmaceuticals or diagnostic agents AVENTIS PHARMA GMBH (DE) 2001-08-22 CN disclosed
EP-1097140-A2 BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM Aventis Pharma Deutschland GmbH (DE) 2001-05-09 EP disclosed
EP-1097141-A1 IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT Aventis Pharma Deutschland GmbH (DE) 2001-05-09 EP disclosed
CN-1289321-A Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament AVENTIS PHARMACEUTIC DEUTSCHLA (DE) 2001-03-28 CN disclosed
EP-1053224-A1 BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT Aventis Pharma Deutschland GmbH (DE) 2000-11-22 EP disclosed
WO-2000003994-A2 BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed
WO-2000003996-A1 IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed
WO-1999040064-A1 BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-08-12 WO disclosed